Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.84 |
| ▸ | BRD2 | P25440 | 6/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | TSPO | P30536 | 1/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.77 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.77 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | BRD1 | O95696 | 1/20 | 0.77 |
| ▸ | CCL2 | P13500 | 1/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.77 |
| ▸ | EP300 | Q09472 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873173 | 1.00 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL7480681 | 1.00 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| Hydrochloric Acid SCHEMBL15900115 | 0.99 | BRD4 (0.98) | BRD4DNERBRD2ADORA3TSPO | |
| Hydrochloric Acid SCHEMBL15900132 | 0.99 | BRD4 (0.98) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL16150161 | 0.94 | BRD4 (0.93) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL15980842 | 0.92 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL19556888 | 0.92 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL18017604 | 0.92 | BRD4 (1.00) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL12228129 | 0.92 | BRD4 (0.85) | BRD4DNERBRD2ADORA3TSPO | |
| SCHEMBL21501421 | 0.91 | BRD4 (0.84) | BRD4DNERBRD2ADORA3TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 715 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468559-B1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-11-22 | — | — | EP | claimed |
| US-20230310452-A1 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | MDI BIOLOGICAL LABORATORY (US) | 2023-10-05 | — | — | US | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| US-11298354-B2 | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-12 | — | — | US | claimed |
| WO-2022046682-A1 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | MDI BIOLOGICAL LABORATORY (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2021262731-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-12-30 | — | — | WO | claimed |
| US-20260109707-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260098043-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMECEUTICAL CO LTD (CN) | 2026-04-09 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| EP-0989131-B1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND MEDICINAL USES THEREOF | MITSUBISHI PHARMA CORP (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0989131-A1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND MEDICINAL USES THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | BRD4 1630/4885DNER 257/4885BRD2 1196/4885 |
| US-20260098043-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR3C2, NR3C1 | BRD4 205/4885DNER 3101/4885BRD2 333/4885 |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | BRD4 265/4885DNER 3109/4885BRD2 318/4885 |
| US-11298354-B2 | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors | HDAC9, HDAC7, HDAC8 | BRD4 15/4885DNER 2588/4885BRD2 30/4885 |
| US-20260109707-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRDT | BRD4 1/4885DNER 1376/4885BRD2 11/4885 |
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | NR2C2, SRR, NCOR2 | BRD4 902/4885DNER 1102/4885BRD2 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.